These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12782586)

  • 1. "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.
    Rybak SM; Sanovich E; Hollingshead MG; Borgel SD; Newton DL; Melillo G; Kong D; Kaur G; Sausville EA
    Cancer Res; 2003 Jun; 63(11):2812-9. PubMed ID: 12782586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
    Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
    Clin Cancer Res; 2002 Jul; 8(7):2389-98. PubMed ID: 12114444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
    Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
    Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
    Rastelli L; Valentino ML; Minderman MC; Landin J; Malyankar UM; Lescoe MK; Kitson R; Brunson K; Souan L; Forenza S; Goldfarb RH; Rabbani SA
    Int J Oncol; 2011 Aug; 39(2):401-8. PubMed ID: 21567086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor.
    Middeke M; Hoffmann S; Hassan I; Wunderlich A; Hofbauer LC; Zielke A
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):386-92. PubMed ID: 12518248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of inflammatory corneal angiogenesis by TNP-470.
    Joussen AM; Beecken WD; Moromizato Y; Schwartz A; Kirchhof B; Poulaki V
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2510-6. PubMed ID: 11581191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
    Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
    Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice.
    Dabrowska-Iwanicka A; Olszewska D; Jalili A; Makowski M; Grzela T; Marczak M; Hoser G; Giermasz A; Golab J; Jakóbisiak M
    J Cancer Res Clin Oncol; 2002 Aug; 128(8):433-42. PubMed ID: 12200600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
    Geng L; Donnelly E; McMahon G; Lin PC; Sierra-Rivera E; Oshinka H; Hallahan DE
    Cancer Res; 2001 Mar; 61(6):2413-9. PubMed ID: 11289107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis.
    Olaso E; Salado C; Egilegor E; Gutierrez V; Santisteban A; Sancho-Bru P; Friedman SL; Vidal-Vanaclocha F
    Hepatology; 2003 Mar; 37(3):674-85. PubMed ID: 12601365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental growth factor upregulation is a host response to antiangiogenic therapy.
    Bagley RG; Ren Y; Weber W; Yao M; Kurtzberg L; Pinckney J; Bangari D; Nguyen C; Brondyk W; Kaplan J; Teicher BA
    Clin Cancer Res; 2011 Mar; 17(5):976-88. PubMed ID: 21343374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cancer therapy targeting tumor-induced neovascularization].
    Sato K; Kato T
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):295-300. PubMed ID: 7509149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
    Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.